Phathom Pharmaceuticals Announces Commercial Availability Of VOQUEZNA Tablets, A Powerful First-In-Class PCAB For The Treatment Of Erosive GERD And Relief Of Associated Heartburn
Portfolio Pulse from Benzinga Newsdesk
Phathom Pharmaceuticals, Inc. has announced the U.S. commercial availability of VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB) for the treatment of Erosive GERD and associated heartburn. VOQUEZNA has demonstrated superiority over lansoprazole in clinical trials and is available through major retail pharmacies and BlinkRx. The company is also preparing to launch VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK for H. pylori infection treatment in mid-December 2023.
November 28, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Phathom Pharmaceuticals' launch of VOQUEZNA could lead to increased revenue and market share in the GERD treatment sector, potentially boosting investor confidence.
The commercial availability of VOQUEZNA represents a significant milestone for Phathom Pharmaceuticals, as it is the first and only FDA-approved PCAB for Erosive GERD. Given the clinical superiority over existing treatments and the high prevalence of GERD, this launch could lead to increased sales and market penetration. The upcoming release of VOQUEZNA TRIPLE PAK and DUAL PAK could further strengthen the company's position in the market. The news is likely to be received positively by investors, potentially leading to a short-term increase in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100